CG Oncology (NASDAQ: CGON) director exercises options and sells 5,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 5,000 shares ($325,000)
Net Sell
3 txns
Insider
POST LEONARD E
Role
null
Sold
5,000 shs ($325K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.60 | $3K |
| Sale | Common Stock | 5,000 | $65.00 | $325K |
Holdings After Transaction:
Director Stock Option (right to buy) — 111,077 shares (Direct, null);
Common Stock — 5,000 shares (Direct, null)
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Fully vested
Key Figures
Shares sold: 5,000 shares
Sale price: $65.00 per share
Option exercise price: $0.60 per share
+4 more
7 metrics
Shares sold
5,000 shares
Common stock sold in open-market transaction on June 22, 2026
Sale price
$65.00 per share
Price for 5,000 common shares sold
Option exercise price
$0.60 per share
Exercise price for director stock options
Options exercised
5,000 options
Director stock options exercised into common stock
Options remaining
111,077 options
Director stock options held after transactions
10b5-1 plan adoption date
March 5, 2026
Date trading plan for sales was adopted
Option expiration
July 8, 2028
Expiration date for remaining director stock options
Key Terms
Rule 10b5-1 trading plan, open-market sale, Director Stock Option (right to buy), derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Director Stock Option (right to buy) financial
"security_title: Director Stock Option (right to buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transactions did CG Oncology (CGON) director Leonard E. Post report?
Leonard E. Post reported exercising options for 5,000 CG Oncology shares at $0.60 and selling 5,000 common shares at $65.00. The filing shows this was an open-market sale combined with an option exercise on June 22, 2026.
What director stock options in CG Oncology (CGON) does Leonard E. Post retain?
He retains 111,077 director stock options with an exercise price of $0.60 per share, expiring on July 8, 2028. These options give him the right to buy CG Oncology common stock at that fixed price before the expiration date.
How large was Leonard E. Post’s CG Oncology (CGON) sale compared with his options position?
He sold 5,000 common shares while retaining 111,077 director stock options. This means the reported sale represents only a small portion of the shares he could acquire through his remaining options, based on the figures in the Form 4.